Page 9 - Jan Mikkelsen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Redwood cityUnited statesNew jerseyBaden wübergJan mikkelsenBart clarkeAscendis pharmaEndocrine societyExchange commissionMayo clinicChief executiveHypoparathyroidism patient experience scaleAscendis pharma investorsPalo altoLooking statements thisAscendi annual report

One-Year Data from Phase 3 Trial of TransCon PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

One-Year Data from Phase 3 Trial of TransCon PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesAscendis pharmaJan mikkelsenBart clarkeEndocrine societyMayo clinicChief executive

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented

- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously reported for the initial 26-week blinded portion of the

New jerseyUnited statesBaden wübergRedwood cityBart clarkeJan mikkelsenAscendis pharmaExchange commissionEndocrine societyMayo clinicChief executiveAscendis pharma investorsPalo altoAscendi annual report

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously reported for the initial 26-week blinded. | June 18, 2023

Redwood cityUnited statesBaden wübergNew jerseyPalo altoJan mikkelsenBart clarkeTim leeMelinda bakerAscendis pharmaEndocrine societyPatti bankGlobenewswire incExchange commissionMayo clinicChief executive

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023 - Ascendis Pharma (NASDAQ:ASND)

- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously reported for the initial 26-week blinded portion of the Phase 3 PaTHway Trial -

New jerseyUnited statesBaden wübergRedwood cityBart clarkeAscendis pharmaJan mikkelsenEndocrine societyMayo clinicChief executiveAscendis pharma investorsPalo alto